Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Conference attendancePharming Group N.V. announces that Pharming’s management will attend the 22nd Annual Needham Virtual Healthcare Conference April 17 - 20, 2023.
Pharming Group N.V. announces that Pharming’s management will attend the 22nd Annual Needham Virtual Healthcare Conference April 17 - 20, 2023.
Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 - 4, 2023 in New York.
Presentation to highlight data from the ongoing long-term open-label extension study of leniolisib, a PI3Kδ inhibitor under investigation for APDS, a rare primary immunodeficiency.
Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Medical Officer, Anurag Relan, will attend the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California, November 7-10, 2022.
Pharming Group N.V. announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference in London, November 15-17, 2022.
Pharming Group N.V. announces that its Chief Financial Officer, Jeroen Wakkerman, will present at the Stifel Healthcare Conference in New York, November 15-16, 2022.
Pharming Group N.V. announces that its Chief Executive Officer, Sijmen de Vries, will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid meeting based in New York, at the Lotte Palace Hotel, September 12-14, 2022.
Pharming announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference 2022, a hybrid meeting based in New York, at 22:00-22:30 CET/16:00-16:30 EDT on 9 June 2022.
Pharming Group announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a primary immunodeficiency.
Pharming announces that Principal Investigator V. Koneti Rao, MD, FRCPA, a staff physician in the Primary Immune Deficiency Clinic at the National Institutes of Health in Bethesda, Maryland, will present positive findings from the Phase III pivotal clinical trial of leniolisib for patients with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) at the Clinical Immunology Society (CIS) 2022 Annual Meeting in Charlotte, North Carolina.
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.